Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

Inclusion Criteria:

- Adult with clinically documented diagnosis of PV.

- Completed Study OPV116910 through Week 60 with one of the following outcomes:

Did not achieve remission by Week 60 of OPV116910. Achieved remission on a steroid dose
>10 milligrams/day. Achieved remission on minimal steroid therapy, but is experiencing a
disease flare/relapse while participating in the first year (yr)of the OPV116910
Individualized Follow up Period (It is recommended subjects are transitioned to the
extension study before the steroid dose is increased).

- A woman is eligible to enter the study if she:

Is of non-childbearing potential: documented as surgically sterile (bilateral tubal
ligation, bilateral oophorectomy, hysterectomy, or hysteroscopic tubal occlusion procedure
with follow-up confirmation of bilateral tubal occlusion) or is postmenopausal without
menses for >2 years. Women who are <2 years postmenopausal are required to have menopausal
status confirmed by follicle-stimulating hormone (FSH) and estradiol levels at the
baseline evaluation. If FSH and estradiol levels do not provide confirmation of menopause,
subject will be considered to be of childbearing potential.

Is of childbearing potential, with a negative pregnancy test at baseline, and agrees to
the consistent and correct use of acceptable methods of contraception (Highly-Effective
Methods for Avoiding Pregnancy) during heterosexual intercourse, beginning when the
subject provides informed consent and lasting until 12 months after last dose of
ofatumumab SC.

Exclusion Criteria:

- Past or current history of hypersensitivity to components of the investigational
product or medically-significant adverse effects (including allergic reactions) from
cetirizine (or antihistamine equivalent) or paracetamol/acetaminophen.

- Prior treatment with any of the following within the specified periods:

Medication and Other Treatment Restrictions Prior to OPV117059 Baseline Any time-
Ofatumumab (Intravenous), total body irradiation, bone marrow transplantation, anti CD4; 6
weeks -Live vaccine 8 weeks- Immunosuppressive or immunomodulatory agents, including:
azathioprine, cyclosporine, dapsone, mycophenolate, methotrexate, tacrolimus 6 months-
Cyclophosphamide, cladribine, plasmapheresis, immunoabsorption, or immunoglobulin therapy,
alemtuzumab, mitoxantrone 18 months -Rituximab or other anti CD20 treatments

- Confirmed PML or neurological findings potentially consistent with PML.

- Evidence or history of clinically significant infection or medical condition
including:

Chronic or ongoing active infectious disease requiring long term systemic treatment,
including, but not limited to, chronic renal infection, chronic chest infection with
bronchiectasis, or active hepatitis C.

Positive test for hepatitis B surface antigen (HbsAg). For HbsAg negative, but hepatitis B
core antibody positive (anti-HBc) (regardless of hepatitis B surface antibody [HbsAb]
status), a hepatitis B virus deoxyribonucleic acid (HBV DNA) test will be performed and
the subject will be excluded if results are positive. Consult with a physician experienced
in the care and management of subjects with hepatitis B to manage/treat subjects who are
anti HBc positive. Subjects who are anti-HBc positive and HBV DNA negative will continue
to be monitored throughout the study.

History of positive serology for human immunodeficiency virus. Previous serious
opportunistic or atypical infections. Prior history, or suspicion, of tuberculosis. A
radiograph of the chest taken within 3 months before the first administration of
investigational product suggests no evidence indicating current active tuberculosis or
previous tuberculosis.

- Past or current malignancy, except for: Cervical carcinoma Stage 1B or less;
Noninvasive basal cell and squamous cell skin carcinoma; Cancer diagnoses with a
duration of complete response (remission) >5 years.

- Clinical chemistry and/or hematology laboratory values of clinical concern, in the
investigator's opinion.

For subjects transitioning directly from the OPV116910 study, review central chemistry and
hematology laboratory reports from the Week 48 through Week 56 visits of OPV116910.

For subjects transitioning from the Individualized Follow-up Period of OPV116910, review
central chemistry and hematology laboratory reports from the most recent OPV116910
Individualized Follow-up visit. If the date of that laboratory report is more than 12
weeks from the extension study Screening visit, then the laboratory assessments need to be
repeated.

For subjects with neutropenia (absolute neutrophil count <1 Giga units per liter, the
neutropenia must resolve before the first dose of ofatumumab, which should occur within 4
weeks of the screening assessments.

- Electrocardiogram (ECG) showing a clinically significant abnormality or showing a
Corrected QT Interval (QTc) interval >=450 millisecond (msec) (>=480 msec for
subjects with bundle branch block) (ECG will be obtained during Week 60 visit of
OPV116910; Repeat ECG if more than 12 weeks have elapsed).

- Significant concurrent, uncontrolled medical condition that could affect the
subject's safety, impair the subject's reliable participation in the study, impair
the evaluation of endpoints, or necessitate the use of medication not allowed by the
protocol.

- In the Investigator's opinion, there is a reason why the subject would not be
eligible for this study (eg, the subject is unable to comply with the visit
schedule).